EUVIMEDEUVIMED entdecken
Crossref

USP14 promotes the cancer stem‐like cell properties of OSCC via promoting SOX2 deubiquitination

Chang Liu iD, Shijie Zhou, Wei Tang iD

Oral Diseases · 2024-10 · 30 (7) · 4255-4265

DOI: 10.1111/odi.14896 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oral Diseases, online erschienen am 20.02.2024. Verfasst von Chang Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Department of Oral and M…. Hauptthemen laut MEDLINE: SOXB1 Transcription Factors, Ubiquitin Thiolesterase, Mouth Neoplasms, Ubiquitination. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: "Cross-disciplinary Innovation Project", West China School of Stomatology, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

USP14 (Ubiquitin‐specific‐processing protease 14) is a deubiquitinating enzyme with oncogenic effects in oral squamous cell carcinoma (OSCC). This study aims to identify new substrates of USP14 and elucidate their role in modulating cancer stem‐like cells (CSCs) in OSCC. Materials and Methods Bioinformatics prediction and docking were performed using UbiBrowser 2.0 and HDOCK, respectively. OSCC cell lines and patient‐derived cells were used for experimental validation, employing co‐immunoprecipitation, cycloheximide chase assays, and tumor sphere formation to evaluate the effects of USP14 on SOX2 stability, ubiquitination, and CSC phenotypes.

Results

USP14 upregulation was associated with worse overall survival and progression‐free interval in OSCC. USP14 interacted with SOX2 with its ubiquitin carboxyl‐terminal hydrolase domain. USP14 knockdown impaired SOX2 stability by increasing its polyubiquitination. Ectopic overexpression of wild‐type USP14, but not the hydrolase‐deficient‐mutant USP14 C114A , enhanced SOX2 stability by reducing polyubiquitination. USP14 knockdown suppressed OSCC cell proliferation, colony formation, and tumor sphere formation in vitro and tumor growth in vivo. However, the reduction of CSC markers following USP14 knockdown was mitigated by overexpressing SOX2 . These findings were verified in OSCC patient‐derived CSC cells.

Conclusion

This study revealed a USP14‐SOX2 axis regulating the CSC properties of OSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SOXB1 Transcription FactorsUbiquitin ThiolesteraseMouth NeoplasmsUbiquitinationNeoplastic Stem CellsHumansCell Line, TumorAnimalsCell ProliferationCarcinoma, Squamous CellMice

Stichwörter der Autor:innen

SOX2USP14cancer stem celloral squamous cell carcinoma

Substanzen

SOXB1 Transcription FactorsSOX2 protein, humanUbiquitin ThiolesteraseUSP14 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan Univ…
  • State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Chang Liu, Wei Tang

Förderung

  • "Cross-disciplinary Innovation Project", West China School of Stomatology, Sichuan University

Zitieren

APA

Liu, C., Zhou, S., & Tang, W. (2024). USP14 promotes the cancer stem‐like cell properties of OSCC via promoting SOX2 deubiquitination. Oral Diseases, 30(7), 4255-4265. https://doi.org/10.1111/odi.14896

Vancouver

Liu C, Zhou S, Tang W. USP14 promotes the cancer stem‐like cell properties of OSCC via promoting SOX2 deubiquitination. Oral Diseases. 2024;30(7):4255-4265. doi:10.1111/odi.14896

BibTeX
@article{Liu2024,
  author = {Liu, Chang and Zhou, Shijie and Tang, Wei},
  title = {USP14 promotes the cancer stem‐like cell properties of OSCC via promoting SOX2 deubiquitination},
  journal = {Oral Diseases},
  year = {2024},
  volume = {30},
  number = {7},
  pages = {4255--4265},
  doi = {10.1111/odi.14896}
}
Kostenlos starten →